Find
7119
related chemicals for you
CAS:62613-82-5
Molecular Formula:C6H10N2O3
4-Hydroxy-2-Oxopyrrolidine-N-Acetamide; 4-Hydroxy-2-Oxo-1-Pyrrolidineacetamid; 4-Hydroxypiracetam; Hydroxypiracetam; 2-(4-Hydroxy-Pyrrolidino-2-On-1-Yl)Ethyl Acetate
Brief Introduction
Oxiracetam (ISF 2522) is a nootropic drug of the racetam family and very mild stimulant. Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.
CAS:628-89-7
Molecular Formula:C4H9ClO2
2-(2-Chloroethoxy)Ethanol
Brief Introduction
For organic synthesis and pharmaceutical intermediates. As an intermediate of Quetiapine.
CAS:63-42-3
Molecular Formula:C12H22O11
Lactobiose; D-Lactose; Lactose,Anhydrous; D-Lactose Anhydrous; Anhydrous Lactose; Screening Lactose; Crushing Lactose
Brief Introduction
This product is a nutritional sweetener, which is widely used in making baby food, candy, margarine, culture medium, color layer absorbent and shaping medicine.
CAS:638-07-3
Molecular Formula:C6H9ClO3
4-Chloro Ethyl Acetoacetate; Ethyl (Chloroacetyl)Acetate; Ethyl G-Chloroacetoacetate; Ethyl 4-Chloroacetoa; 4-Chloro-Acetoacetic acid Ethyl Ester; 4-Chloro-3-oxo-Butanoic acid Ethyl Ester; Ethyl 4-Chloro-3-Oxobutanoate; Ethyl 4-Chloro Aceto Acetate
Brief Introduction
It is used as the intermediate of medicine and pesticide. It is an intermediate of pharmaceutical synthesis and the intermediate of oxiracetam and L-carnitine. Amlodipine besylate for synthesis
CAS:641571-10-0
Molecular Formula:C28H22F3N7O
Tasigna; Nilotinib (Amn-107); Its Intermediates; Nilotinib For Research; Nilotinib(Amn 107); Nilotinib,Amn107,Tasigna; Amn 107; Nilotinib D6
Brief Introduction
Nilotinib is a new targeted tumor therapeutic drug, which belongs to tyrosine kinase inhibitor. It is used to treat patients with chronic myeloid leukemia (CML) resistant to glipizide (imatinib). Gleevec is the preferred drug developed by Novartis for the treatment of chronic myeloid leukemia (CML). Nilotinib is improved from the molecular structure of imatinib. It has stronger selectivity for bcr-abl kinase activity. Its inhibitory effect on tyrosine kinase is 30 times stronger than imatinib. It can inhibit the kinase activity of BCR-ABL mutant resistant to imatinib. It can also inhibit kit and PDGFR kinase activities.
Inquiry ( 
10
 
/ 10
 )
Clear All
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >